Bengaluru-based Jubilant Biosys, a subsidiary of Jubilant Life Sciences, announced the US FDA acceptance of the Investigational New Drug (IND) filing for a novel molecule targeting prostate cancer with Endo Pharmaceuticals of the US. This molecule will now progress towards the next phase of development and is anticipated to go into clinical trials by late 2013.
“We are pleased and elated with this successful outcome, which is the result of excellent collaboration between the scientists at Endo and Jubilant Biosys. Being at the forefront of pharmaceutical, life sciences and healthcare innovation, Jubilant pursues its goal to enable affordable healthcare to patients worldwide,” said Dr Subir Kumar Basak, President, Global Drug Discovery Services, Jubilant Life Sciences.
Dr Sandeep Gupta, Senior Vice President, Discovery & Early Development, Endo Pharmaceuticals, “I congratulate the Jubilant and Endo teams on achieving this important milestone. It was their outstanding collaborative work and ingenuity that enabled the successful filing and acceptance of an IND in less than three years. The IND filing and progression of the molecule to the next stage of development further validates Endo’s unique collaborative drug discovery approach which aims to address unmet medical needs and improve patient outcomes.”
EP News Bureau – Mumbai